الفهرس 
Detection of CD96 in acute myeloid leukemia patients and its relationship to remission induction chemotherapy
AbstractOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Background: Acute myeloid leukemia (AML) remains one of the most difficult malignancies to treat. Despite significant advancements in the understanding of disease biology, yet the relapse of AML remains frequent. Leukemic stem cells (LSCs) play a crucial role in chemotherapy resistance in AML, the classical LSCs phenotype is CD34+/CD38-.Successful eradication of LSCs require combination of different strategies including targeting LSC specific surface molecules. Aim of work: This study aimed for detection of CD96 in newly diagnosed AML as a leukemic stem cell marker and investigating the potential co-association between leukemic stem marker CD96 in de-novo acute myeloid leukemia patients and the response to induction therapy at day 28, to increase the understanding of the role of CD96 in AML diagnosis and prognosis. Patients and Methods: The current study was conducted on 50 patients with de-novo AML, in addition to 20 controls. Patients were selected among groups referred to clinical Hematology and medical oncology departments at Kasr Al- Aini hospital. Using multicolor flowcytometry, we analyzed the expression of CD96 among CD34+/CD38- cell population in AML patients at initial diagnosis and correlate it to the response of induction therapy